171 related articles for article (PubMed ID: 28764784)
1. E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis.
Liu JB; Feng CY; Deng M; Ge DF; Liu DC; Mi JQ; Feng XS
World J Surg Oncol; 2017 Aug; 15(1):139. PubMed ID: 28764784
[TBL] [Abstract][Full Text] [Related]
2. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer.
Siitonen SM; Kononen JT; Helin HJ; Rantala IS; Holli KA; Isola JJ
Am J Clin Pathol; 1996 Apr; 105(4):394-402. PubMed ID: 8604681
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression correlates with histologic type but not tumour grade in invasive breast cancer.
Nurismah MI; Noriah O; Suryati MY; Sharifah NA
Asian Pac J Cancer Prev; 2008; 9(4):699-702. PubMed ID: 19256762
[TBL] [Abstract][Full Text] [Related]
4. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
5. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Subtype of Poorly Differentiated Invasive Ductal Carcinoma of the Breast Based on Vimentin and E-cadherin Expression.
Orlandini LF; Reis FJCD; da Silveira WA; Tiezzi MG; de Andrade JM; Ribeiro-Silva A; Deaton R; Bosland M; Tiezzi DG
Rev Bras Ginecol Obstet; 2018 Dec; 40(12):779-786. PubMed ID: 30359996
[TBL] [Abstract][Full Text] [Related]
7. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.
Aleskandarany MA; Negm OH; Green AR; Ahmed MA; Nolan CC; Tighe PJ; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):339-48. PubMed ID: 24771047
[TBL] [Abstract][Full Text] [Related]
8. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
Ma YH; Wang K; Li L; Lu ZH; Chen J
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
[TBL] [Abstract][Full Text] [Related]
11. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
12. N-cadherin expression in breast cancer: correlation with an aggressive histologic variant--invasive micropapillary carcinoma.
Nagi C; Guttman M; Jaffer S; Qiao R; Keren R; Triana A; Li M; Godbold J; Bleiweiss IJ; Hazan RB
Breast Cancer Res Treat; 2005 Dec; 94(3):225-35. PubMed ID: 16258702
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
14. Significance of E-cadherin expression in triple-negative breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Nomura S; Noda S; Kawajiri H; Ishikawa T; Wakasa K; Hirakawa K
Br J Cancer; 2010 Jul; 103(2):249-55. PubMed ID: 20551954
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
16. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
Turashvili G; Bouchalova K; Bouchal J; Kolar Z
Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
[TBL] [Abstract][Full Text] [Related]
18. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
19. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype.
Mahler-Araujo B; Savage K; Parry S; Reis-Filho JS
J Clin Pathol; 2008 May; 61(5):615-20. PubMed ID: 18156431
[TBL] [Abstract][Full Text] [Related]
20. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
